By Mill Chart
Last update: May 13, 2025
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) stands out as a potential candidate for investors following the CANSLIM strategy. The stock meets several key criteria of the system, including strong earnings growth, high relative strength, and solid fundamentals. Below, we examine why CPRX aligns with CANSLIM principles.
CPRX holds a perfect technical rating of 10/10, supported by a bullish long-term trend and consistent price performance. The stock has gained 44.5% over the past year, outpacing most peers in the biotechnology sector.
Fundamentally, CPRX scores 8/10, with high marks for profitability, growth, and valuation. Its P/E ratio of 13.2 is well below industry averages, making it an attractive growth-at-a-reasonable-price (GARP) candidate.
For a deeper dive, review the full fundamental analysis and technical analysis reports.
Our CANSLIM High Growth screener lists more high-growth stocks that fit this strategy.
This is not investing advice! The article highlights observations at the time of writing, but you should always conduct your own research before making investment decisions.
22.48
-0.33 (-1.45%)
Find more stocks in the Stock Screener
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and an attractive valuation, making it a standout in biotech.
CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A technical uptrend and reasonable valuation add to its appeal.
CATALYST PHARMACEUTICALS INC (CPRX) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, revenue growth, and solid financial health. A detailed analysis highlights its potential for investors.